Pharmacological treatment of eating disorders.

2019 ◽  
pp. 327-346
Author(s):  
Robyn Sysko ◽  
Tom Hildebrandt ◽  
B. Timothy Walsh
Keyword(s):  
Eating Disorders ◽  
Pharmacological Treatment

Pharmacological Treatment of Eating Disorders

2003 ◽  
pp. 223-314 ◽  
Author(s):  
Martina de Zwaan ◽  
James Roerig
Keyword(s):  
Eating Disorders ◽  
Pharmacological Treatment

P.1.h.028 Selective antagonism at CRF1 receptor as a novel pharmacological treatment for binge-type eating disorders

2013 ◽  
Vol 23 ◽  
pp. S259
Author(s):  
M. Micioni Di Bonaventura ◽  
M. Ubaldi ◽  
K. Rice ◽  
M. Massi ◽  
R. Ciccocioppo ◽  
...  
Keyword(s):  
Eating Disorders ◽  
Pharmacological Treatment ◽  
Crf1 Receptor

scholarly journals Psychopharmacological Options in the Multidisciplinary and Multidimensional Treatment of Eating Disorders

2019 ◽  
Vol 13 (1) ◽  
pp. 22-31
Author(s):  
Walter Milano ◽  
Anna Capasso
Keyword(s):  
Eating Disorders ◽  
Bulimia Nervosa ◽  
Social Factors ◽  
Pharmacological Treatment ◽  
Scientific Evidence ◽  
Age Groups ◽  
Evidence Based ◽  
Binge Eating Disorders ◽  
The Subject

Eating Disorders (ED) are a syndrome characterized by persistent alteration of eating behavior and the conditions that cause insufficient ingestion and/or adsorption of foods. There are three different ED diseases: Anorexia Nervosa (AN), Bulimia Nervosa (BN) and Binge Eating Disorders (BED). ED are complex conditions that arise from a combination of long-standing behavioral, emotional, psychological, interpersonal, and social factors. A common trait to all EDs is the incongruous diet, often based on arbitrary parameters, disconnected from physiological needs, with a strong alteration of the sensations of hunger and satiety, to which variations in weight, body composition, health status and quality of life of patients occur. Although EDs are relatively frequent psychiatric disorders in the general population, especially in adolescent and juvenile age groups, evidence based on the scientific evidence of the efficacy of the pharmacological treatment of EDAs remains modest. The currently available international guidelines related to the pharmacological treatment of EDs are currently few and not always adequately informative, as they are affected by the lack of studies on the subject. As a further consequence of this it is not surprising that, with the sole exception of fluoxetine for the treatment of Bulimia Nervosa (BN) symptoms, no psychopharmaceutical has been authorized by national and international regulators for the treatment of ED. This narrative review focuses on the advantages and limitations of drugs used in the treatment of ED.

Eating Disorders, Diabetes Often Comorbid

2005 ◽  
Vol 38 (15) ◽  
pp. 40
Author(s):  
KATE JOHNSON
Keyword(s):  
Eating Disorders
Sign in / Sign up

Export Citation Format

Share Document